{"id":"open-label-adalimumab","safety":{"commonSideEffects":[{"rate":"12-15","effect":"Injection site reactions"},{"rate":"7-10","effect":"Upper respiratory tract infections"},{"rate":"5-8","effect":"Headache"},{"rate":"0.1-0.5","effect":"Tuberculosis reactivation"},{"rate":"2-4","effect":"Serious infections"},{"rate":null,"effect":"Malignancy risk (increased)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adalimumab blocks TNF-α, a key pro-inflammatory cytokine involved in immune-mediated diseases. By preventing TNF-α from binding to its receptors on immune cells and tissue, it suppresses the inflammatory cascade underlying autoimmune and inflammatory conditions. This mechanism has proven effective across multiple chronic inflammatory diseases.","oneSentence":"Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:33.183Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"},{"name":"Psoriasis"},{"name":"Hidradenitis suppurativa"},{"name":"Juvenile idiopathic arthritis"}]},"trialDetails":[{"nctId":"NCT04527380","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2021-04-13","conditions":"Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis","enrollment":101},{"nctId":"NCT06045754","phase":"PHASE4","title":"A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-04-18","conditions":"Crohn's Disease","enrollment":100},{"nctId":"NCT06100744","phase":"PHASE3","title":"A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-07-08","conditions":"Juvenile Psoriatic Arthritis","enrollment":40},{"nctId":"NCT06941376","phase":"PHASE2","title":"An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-08-01","conditions":"Relapsing Polychondritis","enrollment":20},{"nctId":"NCT03153319","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2017-06-05","conditions":"Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI","enrollment":14},{"nctId":"NCT02632175","phase":"PHASE3","title":"Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-11-26","conditions":"Ulcerative Colitis","enrollment":59},{"nctId":"NCT06390436","phase":"PHASE4","title":"Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2025-06","conditions":"Uveitis, Chronic Disease","enrollment":320},{"nctId":"NCT06640517","phase":"PHASE3","title":"Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biocad","startDate":"2024-08-08","conditions":"Plaque Psoriasis","enrollment":140},{"nctId":"NCT05414201","phase":"PHASE4","title":"A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-07-07","conditions":"Non-infectious Intermediate Posterior- or Pan-uveitis","enrollment":87},{"nctId":"NCT05040464","phase":"PHASE3","title":"Comparison of Azathioprine to Methotrexate in Combination Therapy With Adalimumab in Crohn's Disease: an Open-label Randomized Controlled Trial","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2021-08-26","conditions":"Crohn Disease, Azathioprine, Methotrexate","enrollment":166},{"nctId":"NCT03261102","phase":"NA","title":"TDM Guided Early Optimization of ADAL in Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"waqqas.afif","startDate":"2017-01-17","conditions":"Crohn Disease, Drug Monitoring, Inflammatory Bowel Diseases","enrollment":200},{"nctId":"NCT03906136","phase":"PHASE3","title":"AScalate: Treat-to-target in Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-06-04","conditions":"Axial Spondyloarthritis","enrollment":304},{"nctId":"NCT04088409","phase":"PHASE3","title":"A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2019-10-16","conditions":"Uveitis","enrollment":30},{"nctId":"NCT05411211","phase":"","title":"An Observational Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Pediatric Participants With Polyarticular Juvenile Idiopathic Arthritis (pJIA)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-11-10","conditions":"Polyarticular Juvenile Idiopathic Arthritis","enrollment":20},{"nctId":"NCT06849908","phase":"PHASE2","title":"Baricitinib in the Treatment of Intestinal Behçet's Syndrome","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-11-08","conditions":"Behcet Syndrome, Intestinal Type","enrollment":56},{"nctId":"NCT04200547","phase":"NA","title":"Interest of the Dosage of Adalimumab Serum Levels in Crohn's Disease Patients for Prevention of Postoperative Recurrence","status":"TERMINATED","sponsor":"University Hospital, Montpellier","startDate":"2020-01-29","conditions":"Crohn Disease","enrollment":42},{"nctId":"NCT06498089","phase":"PHASE4","title":"A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-06-28","conditions":"Takayasu Arteritis","enrollment":124},{"nctId":"NCT05495568","phase":"PHASE3","title":"To Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Celltrion","startDate":"2022-11-07","conditions":"Moderate to Severe Chronic Plaque Psoriasis","enrollment":367},{"nctId":"NCT04194827","phase":"PHASE4","title":"Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug Monitoring","status":"RECRUITING","sponsor":"Reade Rheumatology Research Institute","startDate":"2020-03-01","conditions":"Rheumatoid Arthritis","enrollment":267},{"nctId":"NCT04798755","phase":"PHASE3","title":"Efficacy, Safety and Costs of Methotrexate, Adalimumab, or Their Combination in Non-infectious Non-anterior Uveitis","status":"UNKNOWN","sponsor":"Hospital San Carlos, Madrid","startDate":"2022-01-12","conditions":"Uveitis","enrollment":192},{"nctId":"NCT05151848","phase":"PHASE4","title":"Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis","status":"UNKNOWN","sponsor":"Chinese SLE Treatment And Research Group","startDate":"2022-01-05","conditions":"Takayasu Arteritis","enrollment":100},{"nctId":"NCT02764762","phase":"PHASE4","title":"Triple Combination Therapy in High Risk Crohn's Disease (CD)","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-04-18","conditions":"Crohn Disease","enrollment":55},{"nctId":"NCT04183608","phase":"PHASE4","title":"A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating Adalimumab","status":"RECRUITING","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","startDate":"2020-01-14","conditions":"Ulcerative Colitis","enrollment":238},{"nctId":"NCT04610476","phase":"PHASE3","title":"Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2020-10-19","conditions":"Psoriatic Arthritis, Withdrawal, Reduction","enrollment":270},{"nctId":"NCT05020730","phase":"PHASE2","title":"Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa","status":"UNKNOWN","sponsor":"Phoenicis Therapeutics","startDate":"2022-05-05","conditions":"Hidradenitis Suppurativa","enrollment":50},{"nctId":"NCT04551352","phase":"PHASE1","title":"A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-10-28","conditions":"Cutaneous Melanoma, Uveal Melanoma, Mucosal Melanoma","enrollment":20},{"nctId":"NCT03100253","phase":"PHASE4","title":"Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation","status":"TERMINATED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2018-03-01","conditions":"Rheumatoid Arthritis","enrollment":208},{"nctId":"NCT03983876","phase":"PHASE1","title":"PK, Safety and Tolerability Study of AVT02 (Adalimumab) Pre-filled Syringe (PFS) vs, AVT02 Autoinjector (AI)","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2019-07-01","conditions":"Phase 1","enrollment":207},{"nctId":"NCT04453137","phase":"PHASE3","title":"Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2020-06-30","conditions":"Plaque Psoriasis","enrollment":567},{"nctId":"NCT02332590","phase":"PHASE3","title":"Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-01-28","conditions":"Rheumatoid Arthritis","enrollment":369},{"nctId":"NCT00730717","phase":"PHASE2","title":"Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum","status":"WITHDRAWN","sponsor":"Wright State University","startDate":"2009-05","conditions":"Pyoderma Gangrenosum","enrollment":""},{"nctId":"NCT00731757","phase":"PHASE2","title":"Efficacy Study of Humira in the Treatment of Cutaneous Sarcoidosis","status":"WITHDRAWN","sponsor":"Wright State University","startDate":"2009-05","conditions":"Sarcoidosis, Cutaneous Sarcoidosis","enrollment":""},{"nctId":"NCT05164198","phase":"PHASE4","title":"REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST)","status":"UNKNOWN","sponsor":"Hanyang University Seoul Hospital","startDate":"2022-01-15","conditions":"Ankylosing Spondylitis, Axial Spondyloarthritis","enrollment":448},{"nctId":"NCT04171414","phase":"PHASE3","title":"A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Celltrion","startDate":"2019-09-09","conditions":"Rheumatoid Arthritis","enrollment":62},{"nctId":"NCT02471118","phase":"PHASE2","title":"Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab (OKINADA)","status":"COMPLETED","sponsor":"CARE ARTHRITIS LTD.","startDate":"2015-03","conditions":"Osteoarthritis, Knee","enrollment":62},{"nctId":"NCT02092467","phase":"PHASE4","title":"Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-03-14","conditions":"Arthritis, Rheumatoid","enrollment":4372},{"nctId":"NCT01166282","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-09","conditions":"Enthesitis Related Arthritis (ERA)","enrollment":46},{"nctId":"NCT01148225","phase":"PHASE3","title":"A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2010-11-23","conditions":"Uveitis","enrollment":424},{"nctId":"NCT00573794","phase":"PHASE3","title":"Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2007-11-28","conditions":"Ulcerative Colitis","enrollment":592},{"nctId":"NCT01064856","phase":"PHASE3","title":"Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA)","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-02","conditions":"Peripheral Spondyloarthritis","enrollment":165},{"nctId":"NCT03311464","phase":"PHASE3","title":"A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-10-27","conditions":"Pyoderma Gangrenosum","enrollment":22},{"nctId":"NCT02506179","phase":"","title":"Impact of Adalimumab on Patient-reported Outcomes in Ulcerative Colitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-08-18","conditions":"Ulcerative Colitis","enrollment":100},{"nctId":"NCT01548768","phase":"PHASE4","title":"RHYTHM (Formerly Escape II Myocardium)","status":"COMPLETED","sponsor":"Columbia University","startDate":"2011-10-10","conditions":"Rheumatoid Arthritis","enrollment":149},{"nctId":"NCT02814175","phase":"PHASE4","title":"A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-08-05","conditions":"Psoriatic Arthritis","enrollment":246},{"nctId":"NCT03151551","phase":"PHASE4","title":"A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-08-24","conditions":"Psoriatic Arthritis","enrollment":566},{"nctId":"NCT00833729","phase":"PHASE4","title":"The Safety & Efficacy of Etanercept in Psoriasis Patients Who Have Not Responded to Adalimumab","status":"COMPLETED","sponsor":"Dermatrials Research","startDate":"2009-02","conditions":"Plaque Psoriasis","enrollment":10},{"nctId":"NCT02065557","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-10-13","conditions":"Ulcerative Colitis","enrollment":101},{"nctId":"NCT00311246","phase":"PHASE2","title":"Trial of Adalimumab in Progressive Sarcoidosis","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2006-04","conditions":"Sarcoidosis","enrollment":11},{"nctId":"NCT02983227","phase":"PHASE2","title":"A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-11-30","conditions":"Rheumatoid Arthritis","enrollment":496},{"nctId":"NCT02904902","phase":"PHASE3","title":"Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-09-06","conditions":"Hidradenitis Suppurativa","enrollment":15},{"nctId":"NCT02489227","phase":"PHASE3","title":"Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Coherus Oncology, Inc.","startDate":"2015-08","conditions":"Plaque Psoriasis","enrollment":545},{"nctId":"NCT04018599","phase":"PHASE1","title":"Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS","status":"COMPLETED","sponsor":"Fresenius Kabi SwissBioSim GmbH","startDate":"2019-07-15","conditions":"Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis","enrollment":216},{"nctId":"NCT00690846","phase":"PHASE2","title":"Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2007-07","conditions":"Pyoderma Gangrenosum","enrollment":""},{"nctId":"NCT02675023","phase":"PHASE1","title":"Assessment of Pharmacokinetics and Safety of M923 Administered Via Auto-injector or Prefilled Syringe, in Healthy Subjects","status":"COMPLETED","sponsor":"Momenta Pharmaceuticals, Inc.","startDate":"2016-01","conditions":"Healthy","enrollment":603},{"nctId":"NCT02198651","phase":"PHASE4","title":"A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-01-05","conditions":"Rheumatoid Arthritis, Musculoskeletal and Connective Tissue Diseases","enrollment":149},{"nctId":"NCT02405780","phase":"PHASE3","title":"A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"Fujifilm Kyowa Kirin Biologics Co., Ltd.","startDate":"2015-06-10","conditions":"Arthritis, Rheumatoid","enrollment":645},{"nctId":"NCT01505491","phase":"PHASE1","title":"Pharmacokinetics and Safety Study of BI 695501 in Healthy Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-12-01","conditions":"Healthy","enrollment":193},{"nctId":"NCT02393378","phase":"PHASE2","title":"Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate","status":"TERMINATED","sponsor":"Takeda","startDate":"2015-04-08","conditions":"Rheumatoid Arthritis","enrollment":7},{"nctId":"NCT03827876","phase":"PHASE4","title":"Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis","status":"RECRUITING","sponsor":"Psoriasis Treatment Center of Central New Jersey","startDate":"2019-01-16","conditions":"Psoriasis","enrollment":30},{"nctId":"NCT02533375","phase":"PHASE3","title":"Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-09-28","conditions":"Generalized Pustular Psoriasis (GPP), Adalimumab, Japanese","enrollment":10},{"nctId":"NCT02499783","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-08-17","conditions":"Crohn's Disease","enrollment":205},{"nctId":"NCT02640612","phase":"PHASE3","title":"Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-01-22","conditions":"Arthritis, Rheumatoid","enrollment":430},{"nctId":"NCT02185014","phase":"PHASE3","title":"Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-08-12","conditions":"Crohn's Disease","enrollment":252},{"nctId":"NCT01550965","phase":"PHASE3","title":"A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-05","conditions":"Ulcerative Colitis","enrollment":463},{"nctId":"NCT00686374","phase":"PHASE3","title":"Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2008-05-01","conditions":"Crohn's Disease","enrollment":100},{"nctId":"NCT01163617","phase":"PHASE2","title":"The Usability and Injection Time of the Physiolis Syringe and Autoinjector in Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-05","conditions":"Rheumatoid Arthritis","enrollment":85},{"nctId":"NCT02862574","phase":"PHASE2","title":"Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2016-12-15","conditions":"Rheumatoid Arthritis","enrollment":15},{"nctId":"NCT01808118","phase":"PHASE3","title":"Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiographic Axial Spondyloarthritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-04-16","conditions":"Axial Spondyloarthritis","enrollment":673},{"nctId":"NCT01866592","phase":"PHASE4","title":"Vascular Inflammation in Psoriasis - Extension Study","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2013-04","conditions":"Psoriasis, Cardiovascular Disease","enrollment":81},{"nctId":"NCT02722044","phase":"PHASE3","title":"Usability of an AI for M923 in Subjects With Moderate to Severe RA","status":"COMPLETED","sponsor":"Momenta Pharmaceuticals, Inc.","startDate":"2016-04","conditions":"Rheumatoid Arthritis","enrollment":33},{"nctId":"NCT01635764","phase":"PHASE3","title":"Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-04","conditions":"Hidradenitis Suppurativa","enrollment":508},{"nctId":"NCT01235689","phase":"PHASE3","title":"Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-02-11","conditions":"Crohn's Disease","enrollment":252},{"nctId":"NCT01543204","phase":"PHASE4","title":"Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab","status":"TERMINATED","sponsor":"Amgen","startDate":"2012-02-01","conditions":"Psoriasis","enrollment":64},{"nctId":"NCT00650156","phase":"PHASE1","title":"Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2007-06","conditions":"Rheumatoid Arthritis","enrollment":24},{"nctId":"NCT00690911","phase":"PHASE2","title":"Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis","status":"WITHDRAWN","sponsor":"Wake Forest University","startDate":"","conditions":"Sarcoidosis","enrollment":""},{"nctId":"NCT01251614","phase":"PHASE3","title":"A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-12","conditions":"Plaque Psoriasis","enrollment":114},{"nctId":"NCT01764997","phase":"PHASE3","title":"An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate","status":"TERMINATED","sponsor":"Sanofi","startDate":"2013-04","conditions":"Rheumatoid Arthritis","enrollment":776},{"nctId":"NCT02114931","phase":"PHASE3","title":"Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2014-04","conditions":"Arthritis, Rheumatoid","enrollment":467},{"nctId":"NCT01162421","phase":"PHASE4","title":"A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-09","conditions":"Rheumatoid Arthritis","enrollment":77},{"nctId":"NCT00814866","phase":"NA","title":"Bone Resorption, Osteoclastogenesis and Adalimumab","status":"COMPLETED","sponsor":"Université de Sherbrooke","startDate":"2008-09","conditions":"Rheumatoid Arthritis","enrollment":28},{"nctId":"NCT01497717","phase":"PHASE3","title":"Efficacy of Humira in Behcet Patients With Arthritis","status":"COMPLETED","sponsor":"Rambam Health Care Campus","startDate":"2013-07","conditions":"Arthritis; Behcet","enrollment":9},{"nctId":"NCT01556672","phase":"PHASE4","title":"Adalimumab-psoriasis and Small Bowel Lesions","status":"COMPLETED","sponsor":"Innovaderm Research Inc.","startDate":"2012-04","conditions":"Plaque Psoriasis, Crohn's Disease","enrollment":100},{"nctId":"NCT02572245","phase":"PHASE1","title":"A Study of PF-06410293 Following Subcutaneous Administration Using A Prefilled Syringe Or A Prefilled Pen In Healthy Adult Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-01","conditions":"Healthy Subjects","enrollment":164},{"nctId":"NCT01958827","phase":"PHASE3","title":"A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-09","conditions":"Crohn's Disease","enrollment":28},{"nctId":"NCT00775437","phase":"PHASE3","title":"Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-03","conditions":"Juvenile Idiopathic Arthritis","enrollment":32},{"nctId":"NCT01604629","phase":"PHASE4","title":"Evaluation of a Protocol for Dose Reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF","status":"COMPLETED","sponsor":"Spanish Clinical Pharmacology Society","startDate":"2012-07","conditions":"Spondylarthropathies","enrollment":120},{"nctId":"NCT00298272","phase":"PHASE2","title":"Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Biogen","startDate":"2006-05","conditions":"Rheumatoid Arthritis","enrollment":54},{"nctId":"NCT01004432","phase":"PHASE3","title":"Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)","status":"COMPLETED","sponsor":"Janssen Biotech, Inc.","startDate":"2009-12","conditions":"Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases","enrollment":433},{"nctId":"NCT01704599","phase":"PHASE1, PHASE2","title":"Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis","status":"TERMINATED","sponsor":"Wayne State University","startDate":"2009-01","conditions":"Psoriasis","enrollment":8},{"nctId":"NCT01752855","phase":"PHASE2","title":"Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-12","conditions":"Rheumatoid Arthritis","enrollment":88},{"nctId":"NCT01644396","phase":"PHASE4","title":"An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-05","conditions":"Moderate to Severe Plaque Psoriasis","enrollment":50},{"nctId":"NCT02252809","phase":"EARLY_PHASE1","title":"Effect of Anti-Inflammatory Agents on Biological Responses to Endotoxin Inhalation in Healthy Subjects","status":"COMPLETED","sponsor":"Brugmann University Hospital","startDate":"2008-11","conditions":"Innate Immunity","enrollment":51},{"nctId":"NCT00963313","phase":"","title":"A 24 Week Open Label Study of the Utility of Adalimumab in Active Axial Forms of Psoriatic Arthritis","status":"COMPLETED","sponsor":"Dr. FRANCISCO J. BLANCO-GARCIA","startDate":"2010-03","conditions":"Psoriatic Arthritis","enrollment":29},{"nctId":"NCT00939003","phase":"PHASE3","title":"Study of Adalimumab in Patients With Axial Spondyloarthritis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-07","conditions":"Axial Spondyloarthritis","enrollment":192},{"nctId":"NCT00853099","phase":"PHASE3","title":"A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-02","conditions":"Ulcerative Colitis","enrollment":274},{"nctId":"NCT01185288","phase":"PHASE4","title":"A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-09","conditions":"Rheumatoid Arthritis","enrollment":309},{"nctId":"NCT01283971","phase":"PHASE4","title":"A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2011-05","conditions":"Rheumatoid Arthritis","enrollment":96},{"nctId":"NCT00714493","phase":"PHASE4","title":"RESTART C0168Z05 Rheumatoid Arthritis Study","status":"COMPLETED","sponsor":"Centocor Ortho Biotech Services, L.L.C.","startDate":"2008-07","conditions":"Rheumatoid Arthritis","enrollment":203},{"nctId":"NCT00195663","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2000-12","conditions":"Early Rheumatoid Arthritis","enrollment":799},{"nctId":"NCT00274352","phase":"PHASE2","title":"A Study of Adalimumab to Treat Sarcoidosis of the Skin","status":"COMPLETED","sponsor":"Pariser, Robert J., M.D.","startDate":"2006-09","conditions":"Sarcoidosis","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ABT-D2E7","Humira","adalimumab"],"phase":"phase_3","status":"active","brandName":"Open-label Adalimumab","genericName":"Open-label Adalimumab","companyName":"AbbVie (prior sponsor, Abbott)","companyId":"abbvie-prior-sponsor-abbott","modality":"Biologic","firstApprovalDate":"","aiSummary":"Adalimumab is an antibody that inhibits tumor necrosis factor, a protein involved in inflammation. It is used to treat conditions such as Sarcoidosis, Rheumatoid Arthritis, Crohn Disease, and Ankylosing Spondylitis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}